TickerTalks
Browse all tickers →
TickerTalks›$SGHT
SGSGHT

Sight Sciences, Inc.

$SGHT·$486M·Medical - Devices·Healthcare
$9.27+3.8%YTD+16.6%1Y+166.4%
Price updated 11h ago·X counts updated 1d ago
SGSGHT
$SGHTSight Sciences, Inc.
$9.27+3.81%2 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SGHT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

2X posts · last 7 days
Sep 11Sep 27

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SGHT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Sight Sciences is up 166% over 12 months at 99% of its 52-week range — TearCare just cleared the first-and-only MGD-treatment indication and BlackRock added.

Sight Sciences is a $490M-cap medical-devices company (glaucoma, dry-eye) whose commercial trajectory has hit a decisive inflection.

  • Up 17% year to date and 166% over the last twelve months, at 99% of its 52-week range and 58% above the 200-day moving average.
  • Q2 revenue $23M grew 20% year over year at 91% gross margin and -17% operating margin, EPS -$0.08.
  • Q1 revenue $20M grew 13% year over year — Q2 acceleration was material.
  • Trailing P/E -13 and price-to-sales 4.6 — the multiples reflect the growth-trajectory optimism.
  • Debt-to-equity 0.79 — moderate leverage.
  • Three surprises of -26 to 56% magnitude — the beat cadence has been strong.
  • TearCare just became the first-and-only MGD treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.
  • BlackRock purchased new shares — institutional accumulation.
  • Analyst-covered next-year consensus is -$0.64 EPS on $90M revenue.

November 5 earnings (est. -$0.13 EPS) will test whether Q3 revenue continues accelerating and whether operating margin narrows further.

What to watch: November 5 print — revenue growth staying above 20%, operating margin narrowing, and any updated commentary on TearCare launch trajectory and OMNI-glaucoma stability.

On the calendar: 2026-11-05 — Q3 earnings

no sentiment samplefloat missingbeta missing

Read the AI verdict on $SGHT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Ophthalmic device company with the OMNI surgical system for minimally invasive glaucoma surgery and TearCare for dry eye.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $SGHT.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $SGHT

Partial — Ophthalmic device company with the OMNI surgical system for minimally invasive glaucoma surgery and TearCare for dry eye.

Industry benchmark

17-name peer basket
+18.0%YTD
+20.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-29.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-33.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-50.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
88.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.08$-0.18+56.4%
Q1 2026May 6, 2026$-0.24$-0.19-26.3%
Q4 2025Mar 4, 2026$-0.08$-0.15+46.7%
Q3 2025Nov 6, 2025$-0.16$-0.26+38.5%
Next earningsThu, Nov 5·consensus EPS $-0.13

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$23.4M+19.5%91.4%-16.6%$-0.08$-12.8M
Q1 FY26$19.7M+12.5%86.2%-63.0%$-0.24$-7.1M
Q4 FY25$20.4M+6.9%87.3%-18.0%$-0.08$-1.7M
Q3 FY25$19.9M-1.2%86.4%-39.7%$-0.16$-8.9M

Forward consensus

3-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$90.4M$90.2M – $90.6M-$0.64-$0.65 – -$0.635
FY27$101.1M$99.7M – $102.3M-$0.60-$0.78 – -$0.435
FY28$109.5M$106.1M – $111.4M-$0.53-$0.80 – -$0.334

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.99%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+24.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+57.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 6Jeremy B. HaydenChief Legal Officer12.7K sh$70KSellJul 6David BadawiCTO7.4K sh$41KSellJul 2Alison BauerleinCOO24.2K sh$130KSellJul 2James RodbergCFO6.9K sh$37KSellJul 1Paul BadawiCEO28.7K sh$155KSellJul 1Brenton TaylorEVP, Operations & R&D2.8K sh$15KBuyJun 10Staffan EncrantzDirector14.1K sh$69KSellMay 18Alison BauerleinCOO12.7K sh$65KSellApr 6James RodbergCFO7.2K sh$26KSellApr 6Jeremy B. HaydenChief Legal Officer13.8K sh$49K
1–10 of 12
+ 6 other (6 awards) in window

See when $SGHT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 183
AI summary

Kashif Rashid, Chief Legal Officer of Sight Sciences, Inc. (SGHT), filed an initial Form 3 disclosing zero shares of common stock beneficially owned as of August 10, 2026. This is a routine Form 3 for a newly appointed executive with no current personal equity position.

8-KOfficer or director changeAug 108-K — Item 5.02: Officer or director change
AI summary

Sight Sciences (SGHT) appointed Kashif Rashid, age 53, as Chief Legal Officer and Corporate Secretary effective August 10, 2026. Rashid previously served as General Counsel of Nevro Corp. This is a C-suite legal leadership appointment.

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Sight Sciences (SGHT) issued a press release on August 5, 2026 announcing Q2 2026 financial results and raised its revenue guidance while reducing adjusted operating expense guidance for the full year 2026. This is a positive guidance revision accompanying earnings. Specific figures are in Exhibit 99.1.

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
8-KPress release / Reg FDMay 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDApr 238-K — Item 7.01: Press release / Reg FD
+ 6 other (2 10-Qs · 2 proxys · 1 SD · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·14d agoBlackRock Inc. Purchases New Shares in Sight Sciences, Inc. $SGHTdefenseworld.net·25d agoSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15globenewswire.com·28d agoTearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Diseaseglobenewswire.com·41d agoSight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcriptseekingalpha.com·54d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$BFLY$BIO$ABT$MDT$BSX$GEHC$SYK
Voices on X · last 7 days

No standout posts about $SGHT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport